Huang Kuei-Yu, Chang Ching-Hao, Hsu Chung-Hua
Chinese Medicine Institute, National Yang-Ming University.
Division of Chinese Medicine, Shin Kong Wu Ho-Su Hospital.
Medicine (Baltimore). 2020 Jul 10;99(28):e21185. doi: 10.1097/MD.0000000000021185.
Coronavirus disease 2019 (COVID-19) is an acute respiratory infectious disease, which is pandemic, infectious, and high mortality. Many commonly discussed medications being used to treat COVID-19 are not without potentially harmful side effects such as heart, liver, kidney problems, or other clinical symptoms. Acupuncture is a nonpharmacological method. When a needle is inserted into an acupuncture point, traumatic physical stimulation occurs, and then the neuroendocrine immune regulation network is activated. This study aimed to evaluate the efficacy of acupuncture for improving the side effects of COVID-19 western medicine treatments.
From their inception to December 10, 2020, the following electronic databases will be searched to identify relevant studies: MEDLINE, PubMed, EMBASE, the Cochrane Library, Chinese National Knowledge Infrastructure (CNKI), and the Chinese Biomedical Literature Database (CBM), without any language restrictions. Randomized controlled trials and credible clinical observations without randomization include patients diagnosed with COVID-19, and receiving western medicine treatments or acupuncture, with no restrictions on disease stage, age, sex, or ethnicity. Primary outcomes would be used to evaluate the mortality rate, C-reactive protein (CRP), creatine, troponin, liver enzymes (aspartate aminotransferase and alanine aminotransferase), blood pressure, clinical symptoms (including fever, fatigue, myalgia, cough, skin rash, nausea, vomiting, and diarrhea), and serum cytokine levels. Secondary outcome would be used to evaluate the adverse events of acupuncture. Risk of bias will be assessed by 2 review authors independently according to the guidelines set out in the Cochrane Handbook for Systematic Reviews of Interventions.
This is the first to evaluate the efficacy of acupuncture for improving the side effects of COVID-19 western medicine treatments. A longer follow-up should be considered in future studies.
This systematic review and meta-analysis would provide evidence of acupuncture specifically focused on its effectiveness and safety for patients with COVID-19 western medications adverse effects.
Registered in the PROSPERO database (CRD42020189494).
2019冠状病毒病（COVID-19）是一种急性呼吸道传染病，具有大流行、传染性强和高死亡率的特点。许多常用于治疗COVID-19的药物并非没有潜在的有害副作用，如心脏、肝脏、肾脏问题或其他临床症状。针灸是一种非药物方法。当针刺入穴位时，会产生创伤性物理刺激，进而激活神经内分泌免疫调节网络。本研究旨在评估针灸改善COVID-19西医治疗副作用的疗效。
从开始到2020年12月10日，将检索以下电子数据库以识别相关研究：MEDLINE、PubMed、EMBASE、Cochrane图书馆、中国知网（CNKI）和中国生物医学文献数据库（CBM），无任何语言限制。随机对照试验和无随机分组的可信临床观察包括诊断为COVID-19并接受西医治疗或针灸的患者，对疾病阶段、年龄、性别或种族无限制。主要结局指标将用于评估死亡率、C反应蛋白（CRP）、肌酸、肌钙蛋白、肝酶（天冬氨酸转氨酶和丙氨酸转氨酶）、血压、临床症状（包括发热、疲劳、肌痛、咳嗽、皮疹、恶心、呕吐和腹泻）以及血清细胞因子水平。次要结局指标将用于评估针灸的不良事件。两名综述作者将根据《Cochrane系统评价干预措施手册》中规定的指南独立评估偏倚风险。
这是首次评估针灸改善COVID-19西医治疗副作用的疗效。未来研究应考虑更长的随访时间。
本系统评价和荟萃分析将为针灸针对COVID-19西医药物不良反应的有效性和安全性提供证据。
已在PROSPERO数据库注册（CRD42020189494）。
